Reimbursement Review Reports


( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Altace HCT Ramipril/hydrochlorothiazide Hypertension List Complete
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled
Altace Plus Felodipine Ramipril/felodipine extended release Hypertension Do not list Complete
Alunbrig Brigatinib NSCLC Do not reimburse Complete
Alunbrig Brigatinib (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) Complete
Alvesco Ciclesonide asthma List Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Anoro Ellipta Umeclidinium/vilanterol Chronic obstructive pulmonary disease List with criteria/condition Complete
Apidra Insulin glulisine Diabetes, Mellitus (Type 1 & 2) List in a similar manner to other drugs in class Complete